ABBV - AbbVie Inc.
202.08
-1.610 -0.797%
Share volume: 5,787,090
Last Updated: Fri 21 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.34%
PREVIOUS CLOSE
CHG
CHG%
$203.69
1.20
0.01%
Fundamental analysis
50%
Profitability
62%
Dept financing
27%
Liquidity
15%
Performance
52%
Performance
5 Days
2.97%
1 Month
19.43%
3 Months
14.20%
6 Months
2.91%
1 Year
14.33%
2 Year
34.12%
Key data
Stock price
$202.08
DAY RANGE
$200.02 - $203.98
52 WEEK RANGE
$153.58 - $207.32
52 WEEK CHANGE
$13.01
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news